This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oldenburg, J. Articles by Fosså, S. D. Search for Related Content PubMed PubMed Citation Articles by Oldenburg, J. Articles by Fosså, S. D. Social Bookmarking                            What's this?

Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis

Jan Oldenburg, Jarad M. Martin, Sophie D. Fosså

From the Department of Clinical Cancer Research, University of Oslo, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; Department of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada

Address reprint requests to Jan Oldenburg, MD, Department of Clinical Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; e-mail: jan.oldenburg{at}medisin.uio.no

Late relapses of malignant germ cell tumors (MGCTs) are rare and occur, by definition, 2 years or later after successful treatment. They represent a major challenge of today's treatment of MGCTs. Because of the rarity and heterogeneity of late relapses, many aspects of their main characteristics remain obscure. We present relevant literature on relapsing MGCTs to highlight the following issues: incidence, impact of initial treatment on the subsequent risk of late relapse, treatment, and survival. In a pooled analysis, the incidence is 1.4% and 3.2% in seminoma and nonseminoma patients, respectively. The predominant site of relapse is the retroperitoneal space in both histologic types. The initial treatment appears to be important for the risk and localization of late relapses. The treatment of late relapses should be based on a representative presalvage biopsy and includes radical surgery and salvage chemotherapy in most cases. Five-year cancer-specific survival is above 50% in the recent large series and reaches 100% in case of single-site teratoma. Diagnosis and treatment of late-relapsing MGCT patients is challenging and should be performed in experienced centers only. Referral of late-relapsing patients to high-volume institutions ensures the best chances of cure and enables increasing understanding of tumor biology and the clinical course of these patients.

Supported by the Research Council of Norway, project No. 160619/V50.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Sato, T. Tanaka, A. Takahashi, M. Sasai, H. Kitamura, N. Masumori, and T. Tsukamoto Late Recurrence and Second Primary Malignancy among 139 Patients with Germ Cell Tumors: Long-term Outcome of the Disease in a Single-center Experience Jpn. J. Clin. Oncol., November 10, 2009; (2009) hyp142v1. [Abstract] [Full Text] [PDF]

				F. Honecker, H. Wermann, F. Mayer, A. J.M. Gillis, H. Stoop, R. J.L.M. van Gurp, K. Oechsle, E. Steyerberg, J. Th. Hartmann, W. N.M. Dinjens, et al. Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors J. Clin. Oncol., May 1, 2009; 27(13): 2129 - 2136. [Abstract] [Full Text] [PDF]

				T. Tandstad, O. Dahl, G. Cohn-Cedermark, E. Cavallin-Stahl, U. Stierner, A. Solberg, C. Langberg, R. M. Bremnes, A. Laurell, H. Wijkstrom, et al. Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program J. Clin. Oncol., May 1, 2009; 27(13): 2122 - 2128. [Abstract] [Full Text] [PDF]

				D. S. Sharp, B. S. Carver, S. E. Eggener, G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor J. Clin. Oncol., December 1, 2008; 26(34): 5524 - 5529. [Abstract] [Full Text] [PDF]

				G. C. Toner Clinical Relevance of "Late" in the Management of Late Relapse After Treatment for a Germ Cell Tumor J. Clin. Oncol., December 1, 2008; 26(34): 5502 - 5503. [Full Text] [PDF]

				C. J. Pezaro, G. Mallesara, and G. C. Toner Late Relapsing Stage I Nonseminoma J. Clin. Oncol., December 1, 2008; 26(34): 5647 - 5648. [Full Text] [PDF]

				S. A. Sohaib, D.-M. Koh, and J. E. Husband The Role of Imaging in the Diagnosis, Staging, and Management of Testicular Cancer Am. J. Roentgenol., August 1, 2008; 191(2): 387 - 395. [Abstract] [Full Text] [PDF]

				K. K. Ang Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes Oncologist, August 1, 2008; 13(8): 899 - 910. [Abstract] [Full Text] [PDF]

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				S. D. Fossa Second Cancers among Survivors of Testicular Cancer: The Emerging Picture ASCO Educational Book, January 1, 2008; 2008(1): 423 - 426. [Abstract] [Full Text] [PDF]

				D. F. Bajorin, R. J. Motzer, and G. J. Bosl Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481. [Full Text] [PDF]